Skip to main content

Clouded Thinking

The Misguided Use of Cost-Effectiveness Analysis and the Implications for Endocrine Interventions

  • Chapter
Evidence-Based Endocrinology

Part of the book series: Contemporary Endocrinology ((COE))

Abstract

Rising health care costs are of concern to policymakers, employers, health care leaders, patients, and citizens all over the world. Health care decision makers struggle to satisfy the increasing demands for health care services associated with aging populations, increasing health care technologies, and changing population expectations using the resources available to the health care system. Notwithstanding, improvements in the level of health of the populations and increasing productivity of health care providers, there appears to be a continuous call for health care systems to do more and to do better. The economics discipline has been identified as providing relevant “toolbox” for dealing with these challenges and there is now over a quarter century of experience of applying an economics way of thinking as an input to health care decision processes. Until recently, this application occurred in an opportunistic, or at least nonsystematic way, within health care systems. In recent years there have been movements in both academic and policymaking environments to promote more systematic and standardized approaches to the use of economics as an input to decision making about the investment in health care programs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Culyer AJ. Economics and Health Economics. In: VanderGang J, Perlman M, eds. Health, Economics, and Health Economics. North Holland, Amsterdam, 1981, pp 3–11.

    Google Scholar 

  2. Williams A. The economic role of health indicators. In: Teeling SG, ed. Measuring the Social Benefit of Medicine. Office of Health Economics, London, 1983, pp. 63–67.

    Google Scholar 

  3. Drummond M, Stoddart G, Torrance G. Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, Oxford, 1987.

    Google Scholar 

  4. Birch S, Gafni A. On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales. Health Econ. 2002;11:185–191.

    Article  PubMed  Google Scholar 

  5. Gafni A, Birch S. Equity considerations in utility-based measures of health outcomes in economic appraisals: an adjustment algorithm. J Health Econ 1991;10:329–342.

    Article  PubMed  CAS  Google Scholar 

  6. LeGrand J. Equity and Choice: An Essay in Economics and Applied Philosophy. Harper Collins, London, 1991.

    Google Scholar 

  7. Mooney G. Economics, Medicine, and Health Care. Wheatsheaf, Brighton, 1986.

    Google Scholar 

  8. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977;296:716–721.

    Article  PubMed  CAS  Google Scholar 

  9. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. Oxford University Press, New York, 1996.

    Google Scholar 

  10. Drummond M, O’Brien B, Stoddart G, Torrance G. Methods for the Economic Evaluations of Health Care Programmes. Oxford University Press, Oxford, 1997.

    Google Scholar 

  11. National Institute for Clinical Excellence. Riluzole for Motor Neurone Disease-Full Guidance. London, 2001.

    Google Scholar 

  12. National Institute for Clinical Excellence, Guide to the Methods of Technology Appraisal (reference N0515). National Institute of Clinical Excellence, London. Available at http://www.nice.org.uk/pdf/brdnov03item3b-pdf. Accessed 2004.

    Google Scholar 

  13. Naylor D. Cost-effectiveness analysis: are the outputs worth the inputs? ACP J Club 1996;124:A12–14.

    PubMed  CAS  Google Scholar 

  14. Coast J. Is economic evaluation in touch with society’s health values? BMJ 2004;329:1233–1236.

    Article  PubMed  Google Scholar 

  15. Williams A. What Could Be Nicer Than NICE? Office of Health Economics, London, 2004.

    Google Scholar 

  16. Wagstaff A. QALYs and the equity-efficiency trade-off. J Health Econ 1991;10:21–41.

    Article  PubMed  CAS  Google Scholar 

  17. Gafni A. Proper preference-based outcome measures in economic evaluations of pharmaceutical interventions. Med Care 1996;34:DS48–DS58.

    PubMed  CAS  Google Scholar 

  18. Gafni A, Birch S. Preferences for outcomes in economic evaluation: an economic approach to addressing economic problems. Soc Sci Med 1995;40:767–776.

    Article  PubMed  CAS  Google Scholar 

  19. Pliskin JS, Shepard DS, Winstein MC. Utility functions for life year and health status. Oper Res 1980;28:206–224.

    Article  Google Scholar 

  20. Vijan S, Hofer TP, Hayward, RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA 2000;283:889–896.

    Article  PubMed  CAS  Google Scholar 

  21. CDC Diabetes Cost Effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002;287:2542–2551.

    Article  Google Scholar 

  22. Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 2003;26:2518–2523.

    Article  Google Scholar 

  23. Arnesen T, Trommald M. Roughly right or precisely wrong? Systematic review of quality-of-life weights elicited with the time trade-off method. J Health Serv Res Policy 2004;9:43–50.

    Article  PubMed  Google Scholar 

  24. Ried W. QALYs versus HYEs: what’s right and what’s wrong. A review of the controversy. J Health Econ 1998;17:607–625.

    Article  PubMed  CAS  Google Scholar 

  25. Cookson R, McDaid D, Maynard A. Wrong SIGN, NICE mess: is national guidance distorting allocation of resources? BMJ 2001;323:743–745.

    Article  PubMed  CAS  Google Scholar 

  26. Devlin N. An introduction to the use of cost-effectiveness thresholds in decision making: what are the issues? In: Towse A, Pritchard C, Devlin N, eds. Cost Effectiveness Thresholds: Economics and Ethical Issues. Kings Fund and Office of Health Economics, London, 2002, pp. 16–21.

    Google Scholar 

  27. Gafni A and Birch S. NICE methodological guidelines and decision making in the National Health Service in England and Wales. Pharmacoeconomics 2003;21:149–157.

    Article  PubMed  Google Scholar 

  28. Weinstein M, Zeckhauser R. Critical ratios and efficient allocation. J Public Econ 1973;2:147–157.

    Article  Google Scholar 

  29. Birch S, Gafni A. Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be? J Health Econ 1992;11:279–296.

    Article  PubMed  CAS  Google Scholar 

  30. Birch S, Gafni A. Changing the problem to fit the solution: Johannesson and Weinstein’s (mis) application of economics to real world problems. J Health Econ 1993;12:469–476.

    Article  PubMed  CAS  Google Scholar 

  31. Sendi P, Gafni A, Birch S. Opportunity costs and uncertainty in the economic evaluation of health care interventions. Health Econ 2002;11:23–31.

    Article  PubMed  CAS  Google Scholar 

  32. Devlin N, Parkin D, Gold M. WHO evaluates NICE. BMJ 2003;327:1061–1062.

    Article  PubMed  Google Scholar 

  33. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn’t it increase at the rate of inflation? Arch Intern Med 2003;163:1637–1641.

    Article  PubMed  Google Scholar 

  34. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473–581.

    PubMed  CAS  Google Scholar 

  35. Laupacis A. Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones? CMAJ 2002;166:44–47.

    PubMed  Google Scholar 

  36. Gafni A, Birch S. Inclusion of drugs in provincial drug benefit programs: Should “reasonable decisions” lead to uncontrolled growth in expenditures? CMAJ 2003;168:849–851.

    PubMed  Google Scholar 

  37. Winkelmayer WC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 2002;22:417–430.

    Article  PubMed  Google Scholar 

  38. King JT, Jr., Justice AC, Aron DC. Management of incidental pituitary microadenomas: a costeffectiveness analysis. J Clin Endocrinol Metab 1997;82:3625–3632.

    Article  PubMed  CAS  Google Scholar 

  39. Gafni A, Birch S. Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. CMAJ 1993;148:913–97.

    PubMed  CAS  Google Scholar 

  40. Gafni A. Economic evaluation of health care interventions: an economist’s perspective. ACP J Club 1996;124:A12–A14.

    PubMed  CAS  Google Scholar 

  41. Maynard A, Sheldon T. Health economics: has it fulfilled its promise? In: Maynard A, Chalmers I, eds. Non-random Reflection on Health Services Research. BMJ Press, London, 1977.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Mayo Foundation for Medical Education and Research

About this chapter

Cite this chapter

Gafni, A. (2006). Clouded Thinking. In: Montori, V.M. (eds) Evidence-Based Endocrinology. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-59745-008-9_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-008-9_15

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-579-8

  • Online ISBN: 978-1-59745-008-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics